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Abstract
Background. A well-functioning vascular access (VA) is
essential to efficient dialysis therapy. Guidelines have been
implemented improving care, yet access use varies widely
across countries and VA complications remain a problem.
This study took advantage of the unique opportunity to uti-
lize data from the Dialysis Outcomes and Practice Patterns
Study (DOPPS) to examine international trends in VA use
andtrendsinpatientcharacteristicsandpracticesassociated
with VA use from 1996 to 2007. DOPPS is a prospective,
observational study of haemodialysis (HD) practices and
patient outcomes at >300 HD units from 12 countries and
hascollecteddatathusfarfrom>35000randomlyselected
patients.
Methods. VA data were collected for each patient at study
entry (1996–2007). Practice pattern data from the facility
medical director, nurse manager and VA surgeon were also
analysed.
Results. Since 2005, a native arteriovenous fistula (AVF)
was used by 67–91% of prevalent patients in Japan, Italy,
Germany, France, Spain, the UK, Australia and New
Zealand, and 50–59% in Belgium, Sweden and Canada.
From 1996 to 2007, AVF use rose from 24% to 47% in the
USA but declined in Italy, Germany and Spain. Moreover,
graft use fell by 50% in the USA from 58% use in 1996
to 28% by 2007. Across three phases of data collection,
patients consistently were less likely to use an AVF ver-
sus other VA types if female, of older age, having greater
body mass index, diabetes, peripheral vascular disease or
recurrent cellulitis/gangrene. In addition, countries with a
greater prevalence of diabetes in HD patients had a signif-
icantly lower percentage of patients using an AVF. Despite
poorer outcomes for central vein catheters, catheter use
rose 1.5- to 3-fold among prevalent patients in many coun-
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tries from 1996 to 2007, even among non-diabetic patients
18–70 years old. Furthermore, 58–73% of patients new to
end-stage renal disease (ESRD) used a catheter for the ini-
tiation of HD in five countries despite 60–79% of patients
having been seen by a nephrologist >4 months prior to
ESRD. Patients were significantly (P < 0.05) less likely to
start dialysis with a permanent VA if treated in a faciity
that (1) had a longer time from referral to access surgery
evaluation or from evaluation to access creation and (2)
had longer time from access creation until first AVF can-
nulation. The median time from referral until access cre-
ation varied from 5–6 days in Italy, Japan and Germany to
40–43daysintheUKandCanada.Comparedtopatientsus-
ing an AVF, patients with a catheter displayed significantly
lower mean Kt/V levels.
Conclusions. Most countries meet the contemporary Na-
tional Kidney Foundation’s Kidney Disease Outcomes
Quality Initiative goal for AVF use; however, there is still
a wide variation in VA preference. Delays between the cre-
ation and cannulation must be improved to enhance the
chancesofafuturepermanentVA.Nativearteriovenousfis-
tula is the VA of choice ensuring dialysis adequacy and bet-
ter patient outcomes. Graft is, however, a better alternative
thancatheterforpatientswherethecreationofanattempted
AVF failed or could not be created for different reasons.
Keywords: arteriovenous fistulae; catheter; DOPPS;
haemodialysis; vascular access
Introduction
A well-functioning vascular access (VA) remains the
Achilles’ heel of haemodialysis (HD) and is essential
to providing efficient dialysis therapy. VA complications
remain the leading cause of morbidity in the HD popula-
tion and account for high healthcare costs. There are three
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main types of access: native arteriovenous fistula (AVF),
AVF graft (AVG) and central vein catheter. Catheter use is
linked to higher rates of infection and could compromise
dialysis adequacy [1,2]. However, AVF provides the best
access for longevity and lowest association with morbid-
ity and mortality [3–6]. Guidelines from different countries
strongly recommend AVF use [7–10].
VA use varies widely across countries [6,11]. AVF use is
linked to patient characteristics, with the use of AVF versus
a graft being lower in patients who are elderly, female, have
peripheral vascular disease, ischaemic cardiac disease, di-
abetes mellitus (DM), obesity, are unable to walk or have
less education [6,12]. However, after accounting for these
differences, HD patients in Europe were 3-fold more likely
to have an AVF in DOPPS I [6]. Surgical practice patterns
might explain this difference in treatment. Instances where
the medical director or the nurse manager expressed a pref-
erence for grafts meant that their patients were more likely
to have a graft over an AVF [13]. The surgeon’s practice
pattern clearly has an impact on the type of VA created
[14]. In new dialysis patients, early referral to a nephrolo-
gistandearlypatienteducationstronglypredictasuccessful
functioning permanent VA at dialysis initiation [12,15–17].
AVF survival is also better when used for the first HD
treatment compared to starting HD with a catheter and then
subsequently using an AVF [6,18,19].
Since VA guidelines have changed during the last
10 years, the present study has used DOPPS data
spanningthistimeperiodtodescribetheimplementationof
change in practice patterns and outcomes following these
guidelines.
Patients and methods
The DOPPS is a prospective, observational study of HD
treatment and patient outcomes. The DOPPS study design
and methodology have been described in detail previously
[20,21]. Briefly, DOPPS I (1996–2001) included data from
randomly selected nationally representative samples of
308 HD units in France (20), Germany (21), Italy (20),
Japan (65), Spain (20), the USA (142) and the UK (20).
DOPPS II (2002–2004) and DOPPS III (2005–2007) in-
cluded the additional participation of 20 HD units each
from Australia, Belgium, Canada and Sweden, and two
from New Zealand. By design, a smaller number of facili-
ties contributed data for DOPPS II, to provide representa-
tive data in the countries of Japan (n = 60) and the USA
(n = 79). Although the majority of sites have provided
data in the USA (n = 64) and the UK (n = 14) in
DOPPS III, data are still being collected in these two
countries to fulfil the target of country facilities. Conse-
quently, DOPPS III results for the UK in particular should
be considered preliminary whereas DOPPS III VA use for
the USA are very similar with US clinical performance
measures data for the year 2006 [22]. Current analyses
were based upon data from 16 402 randomly selected pa-
tients from DOPPS I; 320 HD units and 12 839 patients
from DOPPS II; and 288 HD units and 7921 patients from
DOPPS III.
VA data were collected for each patient at study entry.
The medical director at each facility completed a question-
naire about local practice patterns, including VA prefer-
encesandpractices.Finally,aVAsurgeryquestionnairewas
completed by the primary access surgeon at each facility,
assessing VA practices, training and opinions (DOPPS II).
VAs were classified as one of six types: native AVF, syn-
theticgraft,bovinegraft,tunnelledcentralveincatheter,un-
tunnelled temporary catheter or other. Temporary catheters
were defined as any type or brand of uncuffed, percuta-
neously placed central vein catheter. Analyses that com-
pared AVFs with grafts included both synthetic and bovine
grafts. Some analyses were adjusted for baseline patient
characteristics collected at study entry; age, sex, race,
number of years with end-stage renal disease (ESRD),
body weight and 14 summary comorbid conditions
(listed in Table 2).
Analyses describing access use among prevalent patients
were based upon the access in use at study entry for a
point-prevalent cross-section of patients in each dialysis
unit at the time the unit began participation in the given
studyphase.Analysesdescribingaccessuseamongincident
patients were based upon the access in use at study entry
for patients who were new to ESRD and who had their
first HD treatment for ESRD within 7 days of enrolment
(n = 1131) into the DOPPS.
Sample means and distributions were calculated by the
country for each characteristic. Statistical comparisons
were made between means of country groups using mixed
linear regression for continuous variables and logistic re-
gression for dichotomous variables. Mixed linear regres-
sionmodelsaccountedforfacility-clusteringeffectsusinga
random effects model. An exchangeable correlation matrix
was applied inlogisticmodels using generalized estimating
equations.
AllanalyseswereperformedusingSASversion8.2(SAS
Institute, Cary, NC, USA).
Results
Vascular access use in prevalent patients
AVF and AVG use. TrendsinVAusewereobservedacross
three separate phases of DOPPS data from 1996 to 2006.
VA use varied widely across the 12 DOPPS countries
(Figure 1(a) and (b)), with a high proportion of AVF
(>70%) in Japan, Australia, New Zealand and in the Eu-
ropean countries except for Belgium, the UK and Sweden.
Although AVF use had been much lower in the USA com-
pared with other countries in DOPPS I (1996–2001), the
USA has shown a large improvement in AVF use, nearly
doubling from 24% in DOPPS I to 47% by DOPPS III
(2005–2007). A trend towards greater AVF use was also
observed in Australia, New Zealand and the UK. In con-
trast, AVF use has declined, especially in Spain, Italy and
Germany. DOPPS III data (2005–2007) indicate 4–13% of
HD patients using synthetic or bovine grafts in all countries
except the USA. In all countries studied, graft use has ei-
ther remained the same or has declined over the 10 years of
DOPPSdatacollection, withthelargestreductionobservedVascular access use and outcomes 3221
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Fig. 1. (a) Trends in vascular access use (arteriovenous fistula, catheter or graft) at study entry in DOPPS I, II and III (1996–2007) among prevalent
patient cross-sections in Japan, Italy, Germany, France and Spain. (b) Trends in vascular access use (arteriovenous fistula, catheter or graft) at study
entry in DOPPS I, II and III (1996–2007) among prevalent patient cross-sections in Australia and New Zealand (ANZ) the UK, Belgium, Sweden,
Canada and the United States.
in the USA declining from 58% in DOPPS I (1996–1999)
to 29% in DOPPS III.
Central vein catheter use. Despite higher risks associ-
ated with catheter use at least 23% of prevalent HD pa-
tients used a catheter in the UK, Belgium, Sweden, Canada
and the USA in 2005–2007. The proportion of prevalent
HD patients using a catheter has increased in many Eu-
ropean countries, Canada and the USA (Figure 1(a) and
(b)). Catheter use increased 2- to 3-fold in Italy, Germany,
France and Spain between DOPPS I and DOPPS III. In-
creased dependence upon catheters is not limited to elderly
patients with extensive comorbidities. In non-diabetic HD
patients 18–70 years old, catheter use increased 2-fold in
the USA and >3-fold in France, Germany, Italy and Spain,
from DOPPS I–III (data not shown).
For patients on dialysis >180 days at study entry
(Table 1) 1% of patients had never received a per-
manent access, 56% had received one permanent ac-
cess, 25% had received two, 10% had received three
and 8% had received four or more permanent accesses.
Patients were significantly (P < 0.05) more likely to
have ≥3 prior permanent VAs if they were female or
Table 1. Number of permanent vascular accesses placed in patient prior
to study entry and odds of using a catheter versus permanent access at
study entry
Number of permanent
VA placed in patient
prior to study entry
% of patients AOR catheter
versus
permanent VA
at study entry
P-value
01 . 2 – –
1 55.7 1.00 Reference
2 25.1 1.57 <0.0001
3 9.6 2.91 <0.0001
≥4 8.5 4.92 <0.0001
DOPPS I and II (1996–2004): patients on dialysis >180 days, n = 24 795.
Adjusted for age, race, gender, years with ESRD, 14 summary comorbid
conditions and country. Accounted for facility clustering effects.3222 J. Ethier et al.
black; had congestive heart failure, hypertension, a psychi-
atric disorder, or recurrent cellulitis/gangrene; had longer
time with ESRD; or were treated in facilities taking
at least 2 months to typically first cannulate an AVF
(AOR = 1.39, P = 0.03 versus waiting ≤1 month) or
in facilities not promptly performing VA procedures
(AOR=1.45,P=0.003)(datanotshown).Theoddsofhav-
ing ≥3 prior permanent accesses were lower in Japan than
theUSA(AOR=0.67,P=0.03).Thelikelihoodofpatients
using a catheter versus a permanent VA at study entry in-
creasedmarkedlyasthenumberofpriorpermanentVAsin-
creased(Table1).Forpatientsusingacatheter,9%,56%and
35% had 0, 1–2 or >2 prior permanent VAs, respectively.
Likelihood of AVF use. The relationship of patient
chasracteristics with the likelihood of using an AVF versus
any other VA type was examined for HD patients on
dialysis >180 days in each DOPPS phase. Table 2 results
indicate that patients were consistently less likely to use
an AVF if they were older, had higher body mass index,
diabetes mellitus, peripheral vascular disease or recurrent
cellulitis (including gangrene). For these factors, the
magnitude of the relationship was similar across all the
three study phases. The odds of using an AVF versus other
VA types increased from DOPPS I to III for males and
patients with hypertension.
Vascular access use in incident patients
In nearly half of the countries during DOPPS II, 50% of pa-
tients initiated dialysis with a catheter, ranging from 23%
to 73% (Figure 2). This high catheter use was observed
Table 2. Predictors of fistula versus other access use: consistency across three study cohorts spanning an 11-year time period
Fistula use (versus other access)
DOPPS I (n = 7575) DOPPS II (n = 7995) DOPPS III (n = 6266)
Predictor AOR P-value AOR P-value AOR P-value
Age (per 10 years) 0.92 <0.0001 0.93 0.0001 0.93 0.005
Male (versus female) 1.72 <0.0001 1.95 <0.0001 2.15 <0.0001
BMI (per 1 kg/m2) 0.52 <0.0001 0.53 0.0002 0.53 0.001
Time with ESRD (per year) 1.00 0.34 1.00 0.44 0.98 0.005
CAD 0.87 0.008 0.96 0.45 1.00 0.95
Cancer 0.99 0.95 0.79 0.0003 0.84 0.03
Other cardiovascular 1.05 0.39 1.06 0.24 1.01 0.84
Cerebrovascular disease 1.00 0.97 0.83 0.003 0.93 0.35
CHF 0.90 0.07 0.83 0.002 0.93 0.32
Diabetes 0.85 0.004 0.87 0.007 0.75 <0.0001
GI bleeding 0.79 0.01 1.02 0.80 0.94 0.63
HIV 0.90 0.74 0.96 0.88 0.71 0.51
Hypertension 0.98 0.71 1.13 0.03 1.27 0.0008
Lung disease 0.92 0.37 0.86 0.04 0.92 0.34
Neurologic disease 0.79 0.003 0.82 0.002 0.88 0.15
Psych disorder 1.00 0.96 0.89 0.08 0.79 0.01
PVD 0.81 0.002 0.83 0.003 0.85 0.02
Recurrent cellulitis 0.81 0.02 0.85 0.05 0.75 0.003
Statistically significant values (p < 0.05) are highlighted in bold.
Based upon the access in use at study entry for prevalent cross-sections of patients on dialysis >180 days in DOPPS I (1996–2001), DOPPS II
(2002–2004) and DOPPS III (2005–2007); accounted for facility clustering effects.
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Fig. 2. Vascular access use by country among incident (incident patients entering DOPPS within 7 days of first-ever chronic dialysis; DOPPS II)
haemodialysis patients.Vascular access use and outcomes 3223
Table 3. Percent catheter use by country in patients first seeing a nephrol-
ogist ≥4 months versus <1 month prior to initiating dialysis
Percent catheter use in patients first seeing a
nephrologist ≥4 months versus <1 month
prior to initiating dialysis
<1 month ≥4 months
Country (n = 221) (n = 910)
Australia/New Zealand 93.3 30.7
Belgium 88.9 47.5
Canada 92.9 57.1
France 73.3 25.0
Germany 64.3 15.1
Italy 60.0 31.5
Japan 50.0 n/a
Spain 81.0 25.6
Sweden 61.5 39.7
UK 81.0 64.4
US 88.6 60.6
All countries 77.4 35.7
DOPPS II (2002–2004); incident HD patients on dialysis <7d a y sw h e n
entering DOPPS and who completed a patient questionnaire indicating
when first seeing a nephrologist prior to starting dialysis. Catheter use is
based upon the vascular access in use at study entry.
despite 60–79% of patients seeing a nephrologist >4
months before starting dialysis and 69–88% seeing a
nephrologist>1monthbeforestartingdialysis.Forpatients
seen by a nephrologist <1 month before dialysis start, the
catheter use varied from 50% to >90% in all countries.
For patients having seen a nephrologist >4 months prior
to ESRD onset, catheter use varied from 10% in Japan to
>50% in Canada, the USA and the UK (Table 3).
Factors linked to the proportion of catheter use at dialysis
start. Timely accessibility to a VA surgeon was a fac-
tor influencing the proportion of patients starting dialysis
with a permanent VA. The median time from referral to
VA creation varied widely between countries from 5 to 6
days in Italy, Japan and Germany and from 40 to 43 days
Table 4. The median number of surgeons per facility and per 100 patients
and the median number of patients per facility, by country, DOPPS II
Country Number of
surgeons per
facility
Number of
surgeons per
100 patients
Number of patients
per facility
Australia/New
Zealand
2.5 4.8 53
Belgium 2.0 3.9 52
Canada 2.5 2.3 131
France 2.0 2.8 78
Germany 2.0 2.9 80
Italy 1.0 1.6 55
Japan 1.0 0.5 72
Spain 2.0 5.1 47
Sweden 3.0 5.8 50
UK 3.0 3.6 76
USA 4.0 5.9 76
in Canada and the UK. In most countries the delay be-
tween referral and evaluation by the surgeon (1–18 days)
was shorter than the delay between evaluation and perma-
nent VA creation (7–25 days) (Figure 3). The likelihood of
starting dialysis with a permanent VA versus a catheter was
lower with longer time between referral and evaluation by
the surgeon (AOR 0.89 per 5 days longer, P < 0.0001) and
with longer time between evaluation and access creation
(AOR0.94per5dayslonger,P<0.0001).Therewasawide
variation between countries both in the median number of
VAsurgeonsper100patients(0.5–5.9per100patients)and
the number of surgeons per facility (1.0–4.0 per facility)
(Table 4). In most countries, vascular surgeons represent
the larger group of VA operators. A significant proportion
of VA operators were nephrologists in Italy (85%) and in
Japan(25%),whichexplainsthelowproportionofsurgeons
per 100 patients in these two countries.
Time between AVF creation and cannulation varied. In a
few countries, a high proportion of units (>60%) had their
AVF first cannulated within 4 weeks after AVF creation,
while in most countries units waited >4 weeks before first
AVF cannulation (Figure 4).
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Asignificantlyhigherproportionofpatientswithacatheter
(27.5%) had an spKt/V <1.2 when compared with patients
usingagraft(9.9%)orfistula(19.2%)(P<0.01forcatheter
versusgraftandfistula).Whencomparedwithpatientswith
an AVF or a graft, patients with a catheter generally had
shorter dialysis duration (except in France).
Discussion
The prevailing guideline goals during this study period [7]
were to increase AVF use and limit catheter use. According
to the NKF-KDOQI guidelines in 1997 [23], primary AVF
should be constructed in at least 50% of all new patients.
Ultimately, 40% of prevalent patients should be using an
AVF and <10% maintained on a catheter as their perma-
nent chronic dialysis access. Furthermore, the European
Best Practice Guidelines (EBPG) for VA have strongly
recommended an AVF as the VA of first choice for HD
[10,24]. DOPPS II and III indicate large differences in VA
use across countries. For prevalent patients, all countries
except the USA met the standard of having >40% of pa-
tients dialysing via an AVF in DOPPS I and II, while some
countries had more than twice this target level. Therefore,
this prevailing standard was achievable and has led to a
higher target level in revised guidelines [9]. Although the
USA had a high proportion of graft use, it decreased by
29% between DOPPS I and III while AVF use increased to
47%, now meeting the 1997 KDOQI guidelines. The US
increase in AVF use coincides with a substantial change in
VA preference within US dialysis units as indicated by US
dialysis unit medical director responses. In the USA, AVF
is now the preferred access by 92% of medical director
respondents in DOPPS II, compared to 79% in DOPPS I
[13].DOPPSIdatahaveincreasedmotivationtowardsAVF
creation and implementation of initiatives, such as the Fis-
tulaFirstprogramme[25].Despiteattitudechangestowards
VA, this high proportion might be linked to the preference
orexperienceoftheVAsurgeonintheUSA[6].Intheother
DOPPS Icountries, thehighproportion ofAVFuseslightly
decreased between DOPPS I and III, suggesting that there
might be an increased proportion of patients not suitable
for the creation of an AVF. The increased prevalence of
different comorbidities during the same period and their
interaction could affect the quality of the vascular beds and
impedesuccessfulAVFcreation.The2006revisedKDOQI
clinical practice guidelines for VA have set a goal ≥65%
functional AVF in HD patients. This target increase from
40% to 65% reflects ongoing changes in the US practice
with an incentive to further increase AVF creation.
The <10% goal of prevalent patients with a catheter was
met by five out of seven countries of DOPPS I. In DOPPS
II, 6 out of 11 study regions met or nearly met the <10%
goal. Japan was the only country in DOPPS III to meet
the goal. The increase in diabetes from 18% to 33%, and
vascular disease from 22% to 34% in HD patients between
DOPPS I and III led to higher proportions of patients at
riskforthefailureofAVFcreation.Theincreaseincatheter
use is impressive in the non-diabetic, non-elderly dialysis
population and affects more females. The risk of having
a catheter increases with the number of previous perma-
nent VA attempts and may reflect practices of resorting to
a catheter when repeated permanent access use has been
unsuccessful. Some facility practices and patient character-
istics are linked to high numbers of prior permanent VAs,
which might suggest some changes in VA surgery practice
patterns or expertise. These facility practices are modifi-
able, namely the time for first cannulation and the waiting
time for permanent VA procedure. Surgical expertise most
likely has an impact on the number and longevity of previ-
ous VAs. Our results consistently show from DOPPS I to
III that patients were less likely to be using an AVF if they
were older, obese, diabetic, had peripheral vascular disease
or recurrent cellulitis. Different teams have addressed these
problemsandsuggestedsolutionstoincreaseAVF[26–29].
Despite such efforts, some patients might not be suitable
for the creation of an AVF but could possibly benefit from
a graft. Some countries with a significant proportion of pa-
tientswithcathetershaveaproportionallylowuseofgrafts.
Given the higher mortality rate of catheter patients, a graft
might be a better option for patients not suitable for AVF
creation. The new 2006 KDOQI guidelines have kept theVascular access use and outcomes 3225
goal for catheter use to <10%. Meeting this goal will be a
greatchallengeandwillneedgreatcommitment,teamwork
and the development of specific expertise.
Despite the different published guidelines, there is still
a very high proportion of patients starting dialysis with a
catheter. Late referral to a nephrologic team, which has
been reported in many countries, could be one possible
explanation for the high proportion of catheter use [6,30].
Predialysis care increases the likelihood of a permanent VA
at dialysis start [6]. Our study supports this observation; we
found that the proportion of new patients starting dialysis
with a permanent access was higher when patients were
seen for a longer predialysis period by a nephrologist. The
mean proportion of catheter use in new patients was 77%
and 36% for patients seen by a nephrologist <1 month
and >4 months, respectively, before starting dialysis. The
chance for a patient starting dialysis with a permanent VA
also decreased with longer delays before being seen by a
surgeon and with delays between evaluation and surgery.
Countries with a long median time for AVF creation were
also the countries most reluctant to cannulate AVF early.
In Canada, the UK and the USA >90% of the facilities
typically first cannulate AVF after 4 weeks, thus making
the total time between referral and first AVF cannulation
2–3 months. In these countries, a patient can only start
dialysis with a permanent VA if seen by a nephrologist for
>3–4monthspriortodialysisinitiation.Mendelssohnetal.
[31] have discussed this problem in Canadian care. Fistula
creation at least 4 months before starting chronic HD is
associated with a lower risk of sepsis and death, primarily
by reducing the use of HD catheters [32].
Inadequate dialysis (spKt/V <1.2) was found to be sub-
stantially more common for patients with a catheter. Pre-
vious studies have shown that when compared to AVF it
is possible to provide adequate dialysis with catheters de-
spite flow performances and slightly reduced dialysis doses
[33,34]. Lengthening dialysis time is a simple and efficient
tool to compensate for the reduced flow performances with
catheter use and might explain the better Kt/V of French
dialysis patients with catheters (data not shown).
AVF has a lower frequency of complications and a lower
long-term cost than catheters and grafts, and should there-
fore be favoured as the VA of choice [13]. Catheter use
has been shown to increase mortality risk after adjustment
for many comorbidities or by the use of propensity scores
[2,35,36]. However, other investigators did not find an in-
crease in mortality in patients with catheters [37,38]. De-
spite careful adjustment for various and numerous factors
it remains difficult to account for any bias by indication.
In summary, wide variation in VA use remains across
countries. In the prevalent dialysis population, although the
proportion of AVF meets the 1997 KDOQI guideline goal,
the proportion of catheter use remains a problem. For inci-
dent patients, the high level of catheter use is a matter of
concern and should lead to action. Delays between access
creation and cannulation should be improved, particularly
inviewofRayneretal.’s[18]observationofnodetrimental
consequences upon fistula survival when first cannulated
15 days or longer following creation. More in-depth stud-
ies of factors leading to delays and effects of healthcare
management issues, such as impact of a VA coordinator
and Fistula First program, should be initiated. Creation and
maintenance of a functional AVF will remain the greatest
challenge in the dialysis field. Achievement of target goals
can only be met by dedicated and sustained teamwork and
the development of specific expertise.
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